Trial Condition(s):
Atopic dermatitis
In-home use test of the new modified Diprobase formulation to assess the safety and tolerability in infants and children under physician’s control
Bayer Identifier:
19690
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Trial Purpose
To investigate the safety and tolerability of the modified Diprobase formulation over 14 days in infants and children with a history of Atopic Dermatitis (AD).
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations West Timperley Medical Centre Altrincham, United Kingdom, WA14 5PF | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
In-home use test of the new modified Diprobase® formulation to assess the safety and tolerability in infants and children under physician’s control
Trial Type:
Interventional
Intervention Type:
Device
Trial Purpose:
Treatment
Allocation:
N/A
Blinding:
N/A
Assignment:
Single Group Assignment
Trial Arms:
1
Primary Outcome
- Number of participants with adverse event (AE)Timeframe: Up to 14 days
- Severity of adverse eventThe intensity of an AE is classified according to the following categories: • Mild • Moderate • SevereTimeframe: Up to 14 days
Additional Information
Copyright © Bayer
Powered by
